Legionella y artritis reumatoide en tratamiento con abatacept

Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase iii trial. ATTRACT Study Group, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0 Buch, 2007, Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders, Rheumatology (Oxford), 46, 1153, 10.1093/rheumatology/kem075 Cohen, 2006, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis Rheum, 54, 2793, 10.1002/art.22025 Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, N Engl J Med, 353, 1114, 10.1056/NEJMoa050524 Genovese, 2008, Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy, Ann Rheum Dis, 67, 547, 10.1136/ard.2007.074773 Hyrich, 2004, Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: An update on safety, Ann Rheum Dis, 63, 1538, 10.1136/ard.2004.024737 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Slifman, 2003, Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents, Arthritis Rheum, 48, 319, 10.1002/art.10758 De Rosa, 2003, Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: A possible healthcare-associated case?, Infect Control Hosp Epidemiol, 24, 477, 10.1086/502250 Tai, 2002, Pneumocystis carinii pneumonia following a second infusion of infliximab, Rheumatology (Oxford), 41, 951, 10.1093/rheumatology/41.8.951 Lee, 2002, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept, Arthritis Rheum, 46, 2565, 10.1002/art.10583 Bergstrom, 2004, Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists, Arthritis Rheum, 50, 1959, 10.1002/art.20454 Tubach, 2006, Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists, Clin Infect Dis, 43, e95, 10.1086/508538